Publications by authors named "G R Massa"
Background: "Patient Voices" is a software developed to promote the systematic collection of electronic patient-reported outcome measures (ePROMs) in routine oncology clinical practice.
Objective: This study aimed to assess compliance with and feasibility of the Patient Voices ePROM system and analyze patient-related barriers in an Italian comprehensive cancer center.
Methods: Consecutive patients with cancer attending 3 outpatient clinics and 3 inpatient wards were screened for eligibility (adults, native speakers, and being able to fill in the ePROMs) and enrolled in a quantitative and qualitative multimethod study.
Aim: To evaluate the presence of women on editorial boards and as authors in leading global endodontics journals from 2018 to 2023.
Methodology: The selection of journals was based on the impact factor from Journal Citation Reports (JCR) and CiteScore 2022, with criteria of JCR above 1 and CiteScore above 1.5.
Introduction: KRAS mutation the most common molecular alteration in advanced non-small cell lung cancer (NSCLC) and is associated with an unfavourable prognosis, largely due to the lack of targeted therapeutic options for the majority of the KRAS mutated isoforms. The landscape of NSCLC treatment has expanded with the introduction of immune checkpoint inhibitors (ICIs). Nonetheless, data regarding the efficacy of ICI in NSCLC patients harbouring KRAS mutations are conflicting.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the long-term effects of bilateral testicular regression (BTR) in individuals, focusing on growth and development outcomes, particularly highlighting suboptimal penile growth often related to genetic factors.
- - BTR, a rare condition with potential vascular and genetic origins, was analyzed in a cross-sectional study involving 35 participants recruited from eight pediatric endocrinology departments in Belgium over three years.
- - Key findings revealed common maternal complications during pregnancy and identified specific genetic variants in some participants, while a centralized review of gonadal tissue contributed to understanding the condition's clinical implications.
Article Synopsis
- IRAK4 is a key player in IL-1R and TLR signaling, making it a target for treating autoimmune diseases.
- Researchers developed KT-474, a powerful and selective IRAK4 degrader that can be taken orally, marking it as the first of its kind tested outside of cancer treatment.
- KT-474 has completed phase I trials in healthy individuals and patients with skin conditions, and has advanced to phase II trials for further evaluation.